NCCN Guidelines Revisions and ASCO 2024 Research Outlook

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

EP: 1.NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer

EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024

EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

EP: 4.Tailoring CDK4/6 Inhibitor Treatment to Patient Needs

EP: 5.NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib

EP: 6.Exploring Results from CAPItello-291 Trial

EP: 7.Exploring Biomarker Testing and Personalized Treatments in Breast Cancer

Now Viewing

EP: 8.NCCN Guidelines Revisions and ASCO 2024 Research Outlook

EP: 9.Emerging Breast Cancer Therapies and Closing Thoughts

1. How do you think the revised NCCN Guidelines for breast cancer will impact patient outcomes?
2. What data, results, or insights are you looking forward to coming out of ASCO 2024?

Related Videos

Related Content

Advertisement

August 14th 2025

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

Mario Enrico Canonico, MD, PhD Judith Hsia, MD Shih-Ting Chiu, PhD Pu-Kai Tseng James O. Mudd, MD Joshua D. Remick, MD Bansi Patel, MS Ya-Hsiu Chuang, PhD Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Marc P. Bonaca, MD, MPH

August 14th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

August 14th 2025

Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients

Pierantonio Russo, MD Henriette Coetzer, MD Erik M. Hendrickson, PhD Kenneth Boyle, DC Brent Wright, DrPH

August 14th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

August 14th 2025

Care Quality Metrics in Medicare During COVID-19 Pandemic

Jeanette Thornton, MPA Mark Hamelburg, JD Lynn Nonnemaker, PhD Sherzod Abdukadirov, PhD German Veselovskiy, MPP Sari Siegel, PhD

August 14th 2025

Switching Biologics in Psoriasis Boosts Effectiveness but Raises Infection Risk

Pearl Steinzor

Related Content

Advertisement

August 14th 2025

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

Mario Enrico Canonico, MD, PhD Judith Hsia, MD Shih-Ting Chiu, PhD Pu-Kai Tseng James O. Mudd, MD Joshua D. Remick, MD Bansi Patel, MS Ya-Hsiu Chuang, PhD Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Marc P. Bonaca, MD, MPH

August 14th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

August 14th 2025

Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients

Pierantonio Russo, MD Henriette Coetzer, MD Erik M. Hendrickson, PhD Kenneth Boyle, DC Brent Wright, DrPH

August 14th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

August 14th 2025

Care Quality Metrics in Medicare During COVID-19 Pandemic

Jeanette Thornton, MPA Mark Hamelburg, JD Lynn Nonnemaker, PhD Sherzod Abdukadirov, PhD German Veselovskiy, MPP Sari Siegel, PhD

August 14th 2025

Switching Biologics in Psoriasis Boosts Effectiveness but Raises Infection Risk

Pearl Steinzor